TapewireFind a company

person · Reporting owner

Patel Sujal M

Disclosed activity across 1 company

Tapewire entity
62836
SEC CIK
0001378830

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Nautilus Biotechnology, Inc.NAUT · Entity 6679Director · CEO, President, and Secretary · 10% ownerMarch 04, 2026March 04, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Nautilus Biotechnology, Inc.

Report date March 04, 2026 · Filed March 04, 2026

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Common StockSEC Table I · non-derivativeDirect10,366,721 Reported balance After 2026-03-04 transaction · row 1
1 source row

Row 1 · 2026-03-04 · Purchase · Acquired 25,000 · Balance 10,366,721

F1: Represents the weighted average share price of an aggregate total of 25,000 shares purchased in the price range of $2.48 to $2.6095 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Common StockSEC Table I · non-derivativeIndirectBy PFV I, LLC5,280,476 Reported balance Holding disclosure · report date 2026-03-04 · row 2 Holding and transaction disclosures are not merged.
1 source row

Row 2 · Balance 5,280,476

F2: Shares held by PFV I, LLC. The reporting person is the manager of PFV I, LLC.

Common StockSEC Table I · non-derivativeIndirectBy Sujal Patel 2020 Children's Trust, u/a/d December 3, 20201,814,035 Reported balance Holding disclosure · report date 2026-03-04 · row 3 Holding and transaction disclosures are not merged.
1 source row

Row 3 · Balance 1,814,035

F3: Shares held by Sujal Patel 2020 Children's Trust, u/a/d December 3, 2020 (the "Patel Trust"). The reporting person and the reporting person's spouse are the trustees of the Patel Trust.

Filing footnotes · ownership attribution and instrument terms

F1: Represents the weighted average share price of an aggregate total of 25,000 shares purchased in the price range of $2.48 to $2.6095 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

F2: Shares held by PFV I, LLC. The reporting person is the manager of PFV I, LLC.

F3: Shares held by Sujal Patel 2020 Children's Trust, u/a/d December 3, 2020 (the "Patel Trust"). The reporting person and the reporting person's spouse are the trustees of the Patel Trust.

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
March 04, 2026 Filed Mar 4, 2026 23:37 UTC Nautilus Biotechnology, Inc. NAUT · Entity 6679 PurchaseCommon Stock 25,000 $2.61 $65,237.50
Disclosure

SEC source: 0001378830-26-000003 · wk-form4_1772667437.xml · nonDerivative · entry 1

Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,366,721

F1 · price: Represents the weighted average share price of an aggregate total of 25,000 shares purchased in the price range of $2.48 to $2.6095 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Read SEC document
March 02, 2026 Filed Mar 4, 2026 22:31 UTC Nautilus Biotechnology, Inc. NAUT · Entity 6679 GrantStock Option (Right to Buy) · Derivative 650,000 $0.00 Strike: $2.32 $0.00
Disclosure

SEC source: 0001378830-26-000001 · wk-form4_1772663485.xml · derivative · entry 1

Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 650,000

Underlying: Common Stock · 650,000 shares

Expires 2036-03-02

F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2026.

Read SEC document
September 08, 2025 Filed Sep 9, 2025 20:42 UTC Nautilus Biotechnology, Inc. NAUT · Entity 6679 PurchaseCommon Stock 83,500 $0.68 $57,030.50
Disclosure

SEC source: 0001378830-25-000003 · wk-form4_1757450542.xml · nonDerivative · entry 2

Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,341,721

F2 · price: Represents the weighted average share price of an aggregate total of 83,500 shares purchased in the price range of $0.6581 to $0.7145 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Read SEC document
September 05, 2025 Filed Sep 9, 2025 20:42 UTC Nautilus Biotechnology, Inc. NAUT · Entity 6679 PurchaseCommon Stock 116,500 $0.67 $78,544.30
Disclosure

SEC source: 0001378830-25-000003 · wk-form4_1757450542.xml · nonDerivative · entry 1

Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,258,221

F1 · price: Represents the weighted average share price of an aggregate total of 116,500 shares purchased in the price range of $0.6547 to $0.6899 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Read SEC document
March 20, 2025 Filed Mar 21, 2025 20:44 UTC Nautilus Biotechnology, Inc. NAUT · Entity 6679 PurchaseCommon Stock 23,933 $1.00 $23,889.92
Disclosure

SEC source: 0001808805-25-000034 · wk-form4_1742589871.xml · nonDerivative · entry 2

Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,141,721

F2 · price: Represents the weighted average share price of an aggregate total of 23,933 shares purchased in the price range of $0.9351 to $1.06 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Read SEC document
March 19, 2025 Filed Mar 21, 2025 20:44 UTC Nautilus Biotechnology, Inc. NAUT · Entity 6679 PurchaseCommon Stock 53,300 $0.99 $53,028.17
Disclosure

SEC source: 0001808805-25-000034 · wk-form4_1742589871.xml · nonDerivative · entry 1

Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,117,788

F1 · price: Represents the weighted average share price of an aggregate total of 53,300 shares purchased in the price range of $0.9469 to $1.10 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Read SEC document
March 03, 2025 Filed Mar 4, 2025 21:51 UTC Nautilus Biotechnology, Inc. NAUT · Entity 6679 GrantStock Option (Right to Buy) · Derivative 650,000 $0.00 Strike: $1.24 $0.00
Disclosure

SEC source: 0001808805-25-000020 · wk-form4_1741125091.xml · derivative · entry 1

Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 650,000

Underlying: Common Stock · 650,000 shares

Expires 2035-03-03

F1 · derivative.exercise_date: 25% of the shares subject to the Option shall vest and become exercisable on the first anniversary of the Vesting Commencement Date, as defined below, and the balance of the shares subject to the Option shall vest and become exercisable on a ratable, monthly basis over the 36 months succeeding such first anniversary so long as the Reporting Person remains a Service Provider as provided in the Issuer's 2021 Equity Incentive Plan. Vesting Commencement Date shall mean January 1, 2025.

Read SEC document
March 11, 2024 Filed Mar 12, 2024 00:21 UTC Nautilus Biotechnology, Inc. NAUT · Entity 6679 PurchaseCommon Stock 12,044 $2.84 $34,215.80
Disclosure

SEC source: 0001808805-24-000026 · wk-form4_1710202909.xml · nonDerivative · entry 2

Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,064,488

F2 · price: Represents the weighted average share price of an aggregate total of 12,044 shares purchased in the price range of $2.75 to $3.00 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Read SEC document
March 08, 2024 Filed Mar 12, 2024 00:21 UTC Nautilus Biotechnology, Inc. NAUT · Entity 6679 PurchaseCommon Stock 2,430 $2.99 $7,262.06
Disclosure

SEC source: 0001808805-24-000026 · wk-form4_1710202909.xml · nonDerivative · entry 1

Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,052,444

F1 · price: Represents the weighted average share price of an aggregate total of 2,430 shares purchased in the price range of $2.96 to $3.00 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Read SEC document
March 07, 2024 Filed Mar 8, 2024 00:06 UTC Nautilus Biotechnology, Inc. NAUT · Entity 6679 PurchaseCommon Stock 18,854 $2.89 $54,423.96
Disclosure

SEC source: 0001628280-24-009754 · wk-form4_1709856399.xml · nonDerivative · entry 3

Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,050,014

F3 · price: Represents the weighted average share price of an aggregate total of 18,854 shares purchased in the price range of $2.72 to $3.00 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Read SEC document
March 06, 2024 Filed Mar 8, 2024 00:06 UTC Nautilus Biotechnology, Inc. NAUT · Entity 6679 PurchaseCommon Stock 9,267 $2.70 $25,033.87
Disclosure

SEC source: 0001628280-24-009754 · wk-form4_1709856399.xml · nonDerivative · entry 2

Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,031,160

F2 · price: Represents the weighted average share price of an aggregate total of 9,267 shares purchased in the price range of $2.64 to $2.77 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Read SEC document
March 05, 2024 Filed Mar 8, 2024 00:06 UTC Nautilus Biotechnology, Inc. NAUT · Entity 6679 PurchaseCommon Stock 7,405 $2.65 $19,596.59
Disclosure

SEC source: 0001628280-24-009754 · wk-form4_1709856399.xml · nonDerivative · entry 1

Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 10,021,893

F1 · price: Represents the weighted average share price of an aggregate total of 7,405 shares purchased in the price range of $2.58 to $2.69 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Read SEC document
March 01, 2024 Filed Mar 5, 2024 21:52 UTC Nautilus Biotechnology, Inc. NAUT · Entity 6679 GrantStock Option (Right to Buy) · Derivative 650,000 $0.00 Strike: $2.72 $0.00
Disclosure

SEC source: 0001808805-24-000024 · wk-form4_1709675514.xml · derivative · entry 1

Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 650,000

Underlying: Common Stock · 650,000 shares

Expires 2034-03-01

F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2024.

Read SEC document
February 27, 2023 Filed Mar 1, 2023 22:20 UTC Nautilus Biotechnology, Inc. NAUT · Entity 6679 GrantStock Option (Right to Buy) · Derivative 650,000 $0.00 Strike: $2.00 $0.00
Disclosure

SEC source: 0001808805-23-000032 · wf-form4_167770917669467.xml · derivative · entry 1

Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 650,000

Underlying: Common Stock · 650,000 shares

Expires 2033-02-27

F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is January 1, 2023.

Read SEC document
August 08, 2022 Filed Aug 8, 2022 23:48 UTC Nautilus Biotechnology, Inc. NAUT · Entity 6679 PurchaseCommon Stock 8,346 $2.93 $24,443.76
Disclosure

SEC source: 0001808805-22-000089 · wf-form4_166000250690193.xml · nonDerivative · entry 2

Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,014,488

F2 · price: Represents the weighted average share price of an aggregate total of 8,346 shares purchased in the price range of $2.90 to $3.00 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Read SEC document
August 05, 2022 Filed Aug 8, 2022 23:48 UTC Nautilus Biotechnology, Inc. NAUT · Entity 6679 PurchaseCommon Stock 41,654 $2.92 $121,646.34
Disclosure

SEC source: 0001808805-22-000089 · wf-form4_166000250690193.xml · nonDerivative · entry 1

Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,006,142

F1 · price: Represents the weighted average share price of an aggregate total of 41,654 shares purchased in the price range of $2.76 to $3.00 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Read SEC document
May 09, 2022 Filed May 11, 2022 00:28 UTC Nautilus Biotechnology, Inc. NAUT · Entity 6679 PurchaseCommon Stock 50,000 $3.96 $198,000.00
Disclosure

SEC source: 0001808805-22-000054 · wf-form4_165222886775160.xml · nonDerivative · entry 1

Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,964,488

F1 · price: Represents the weighted average share price of an aggregate total of 50,000 shares purchased in the price range of $3.8299 to $4.00 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Read SEC document
March 04, 2022 Filed Mar 4, 2022 22:39 UTC Nautilus Biotechnology, Inc. NAUT · Entity 6679 Exercise / conversionCommon Stock 100 $10.00 $1,000.00
Disclosure

SEC source: 0001808805-22-000026 · wf-form4_164643353372172.xml · nonDerivative · entry 2

Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,914,488

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

Read SEC document
March 03, 2022 Filed Mar 4, 2022 22:39 UTC Nautilus Biotechnology, Inc. NAUT · Entity 6679 Exercise / conversionStock Option (Right to Buy) · Derivative 100 $0.00 Strike: $10.00 $0.00
Disclosure

SEC source: 0001808805-22-000026 · wf-form4_164643353372172.xml · derivative · entry 5

Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 788,733

Underlying: Common Stock · 100 shares

Expires 2031-01-31

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the Nautilus Subsidiary, Inc. 2017 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement date is January 31, 2021.

Read SEC document
March 03, 2022 Filed Mar 4, 2022 22:39 UTC Nautilus Biotechnology, Inc. NAUT · Entity 6679 PurchaseCommon Stock 50,000 $3.60 $179,890.00
Disclosure

SEC source: 0001808805-22-000026 · wf-form4_164643353372172.xml · nonDerivative · entry 1

Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,914,388

F1 · price: Represents the weighted average share price of an aggregate total of 50,000 shares purchased in the price range of $3.57 to $3.60 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Read SEC document
February 25, 2022 Filed Feb 26, 2022 01:09 UTC Nautilus Biotechnology, Inc. NAUT · Entity 6679 GrantStock Option (Right to Buy) · Derivative 400,000 $0.00 Strike: $3.78 $0.00
Disclosure

SEC source: 0001808805-22-000023 · wf-form4_164583775921533.xml · derivative · entry 1

Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 400,000

Underlying: Common Stock · 400,000 shares

Expires 2032-02-25

F1 · derivative.exercise_date: Subject to reporting person's continuous status as a "Service Provider" (as defined in the the Issuer's 2021 Equity Incentive Plan) through each vesting date, twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of the Vesting Commencement Date (as defined below), and one thirty-sixth (1/36th) of the remaining shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). The Vesting Commencement Date is February 25, 2022.

Read SEC document
December 01, 2021 Filed Dec 2, 2021 13:49 UTC Nautilus Biotechnology, Inc. NAUT · Entity 6679 PurchaseCommon Stock 88,022 $4.73 $416,396.87
Disclosure

SEC source: 0001808805-21-000027 · wf-form4_163845298373636.xml · nonDerivative · entry 2

Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,864,388

F2 · price: Represents the weighted average share price of an aggregate total of 88,022 shares purchased in the price range of $4.44 to $5.00 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Read SEC document
November 30, 2021 Filed Dec 2, 2021 13:49 UTC Nautilus Biotechnology, Inc. NAUT · Entity 6679 PurchaseCommon Stock 161,978 $4.72 $764,779.13
Disclosure

SEC source: 0001808805-21-000027 · wf-form4_163845298373636.xml · nonDerivative · entry 1

Patel Sujal M · CIK 0001378830 · Director · CEO, President, and Secretary · 10% owner

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 9,776,366

F1 · price: Represents the weighted average share price of an aggregate total of 161,978 shares purchased in the price range of $4.48 to $4.85 by the reporting person. The reporting person undertakes to provide upon request by the Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.